IgG4-Related Disease Market Summary
The IgG4-Related Disease market is witnessing a transformative period of growth and clinical advancement. Valued at approximately USD 182 million in 2025 across the 7 Major Markets (7MM), the market is projected to expand at a remarkable CAGR of 34.60% through 2034, driven by rising disease awareness, improved diagnostic capabilities, and a rapidly evolving therapeutic pipeline. Key geographies fueling this momentum include the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan — collectively representing the most mature and commercially significant markets for IgG4-RD treatment.
IgG4-RD Overview
IgG4-Related Disease (IgG4-RD) is a systemic fibro-inflammatory disease characterized by dense infiltration of IgG4-positive plasma cells in affected tissue(s), with or without elevated plasma levels of IgG4. This chronic fibroinflammatory disorder affects a wide range of organs, making it one of the more diagnostically complex conditions in modern medicine. Elevation of serum IgG4 concentrations and abundant infiltration of IgG4-expressing plasma cells are the key diagnostic hallmarks of this autoimmune disease.
Common organ involvement includes the salivary glands, pancreas, and bile duct, though hepatic involvement is less well-established. IgG4-RD may present across a broad spectrum of clinical entities, including:
- Mikulicz’s disease
- Autoimmune pancreatitis
- Hypophysitis and Riedel thyroiditis
- Interstitial pneumonitis and interstitial nephritis
- Prostatitis, lymphadenopathy, and retroperitoneal fibrosis
- Inflammatory aortic aneurysm and inflammatory pseudotumor
IgG4-RD Diagnosis
Diagnosis of IgG4-RD is particularly challenging due to its capacity to simultaneously affect multiple organs. A comprehensive diagnostic workup incorporating clinical, endoscopic, radiographic, and serological assessments is essential to evaluate organ involvement and identify end-organ damage such as hormonal imbalances. Tissue diagnosis through biopsy of affected organ tissue – including the skin – remains necessary for definitive confirmation.
Serum IgG4 concentration is the most critical biomarker, with elevated levels present in up to 90% of patients. While declining IgG4 levels often reflect treatment response, normalization may never occur in some patients, even during remission, due to long-lived plasma cells. Other important biomarkers include IgG1, IgE, eosinophilia, and complement levels (C3 and C4). Hypocomplementemia is notably observed in IgG4-related kidney disease, providing additional diagnostic guidance.
IgG4-RD Treatment
Not all patients with IgG4-RD require immediate treatment – in asymptomatic cases, a strategy of attentive observation is considered appropriate. However, when essential organs are involved or significant symptoms are present, prompt therapeutic intervention becomes critical.
According to the International Consensus Statement on the treatment of IgG4-RD, glucocorticoids represent the first-line therapy, delivering dramatic clinical responses in the majority of patients with both pancreatic and extra-pancreatic involvement. Prednisone is commonly used as the initial step in remission induction, with most patients showing response within days to weeks and achieving remission within months.
To mitigate the adverse effects of prolonged glucocorticoid use and to maintain remission, steroid-sparing agents are employed, including azathioprine, mycophenolate mofetil, methotrexate, cyclophosphamide, and bortezomib. Although evidence for their efficacy remains limited, these agents continue to play a role in maintenance therapy. Rituximab, which depletes CD20-positive plasmablast precursors and thereby reduces IgG4 synthesis, has emerged as a more recent and promising therapeutic alternative – particularly for patients who are refractory or intolerant to glucocorticoids.
IgG4-RD Epidemiology
As reflected in the IgG4-Related Disease market research, epidemiological data are foundational to understanding the patient population and commercial landscape. Forecasted epidemiology is segmented by total diagnosed prevalent cases, gender-specific cases, and age-specific cases across the 7MM from 2020 to 2034.
Key Epidemiological Findings:
- In 2024, total diagnosed prevalent cases of IgG4-RD in the United States stood at approximately 56,800, with projections indicating continued growth through 2034
- Gender-specific analysis in the US revealed approximately 39,100 cases in males and 17,700 cases in females – reflecting a clear male predominance
- The EU4 countries and the UK collectively recorded approximately 53,550 diagnosed prevalent cases in 2024, with males accounting for approximately 38,850 cases and females for approximately 14,750 cases
- In Japan, age-stratified analysis across six groups (0–17, 18–29, 30–44, 45–64, 65–74, and ≥75 years) identified the highest burden in the ≥75 years age group, with approximately 12,800 cases in 2024 – a figure expected to rise through the forecast period.
IgG4-RD Market Recent Developments and Breakthroughs
The IgG4-Related Disease market trends have been shaped by pivotal regulatory and clinical milestones, including:
- In April 2025, IgG4-RD was highlighted for its wide-ranging systemic impact across organs including the pancreas, kidneys, and lungs – characterized by IgG4-positive plasma cell accumulation and elevated blood IgG4 levels
- In April 2025, Amgen announced FDA approval of UPLIZNA (inebilizumab) as the first-ever approved treatment for adults with IgG4-RD – a landmark regulatory milestone for this rare and underserved disease. The drug received Breakthrough Therapy Designation in recognition of its potential to address a serious and previously unmet medical need
Leading IgG4-Related Disease Companies
The competitive landscape is increasingly active, with several key players advancing both marketed and investigational therapies. Leading companies developing potential therapies include Zenas BioPharma, Bristol Myers Squibb, Amgen, Sanofi, and others.
IgG4-Related Disease Marketed Drugs
- UPLIZNA (inebilizumab) – Amgen
UPLIZNA is a humanized monoclonal antibody that causes targeted and sustained depletion of CD19+ B cells – including plasmablasts and some plasma cells – which are key drivers of the autoantibody-mediated disease process. Following two initial infusions, patients require one dose every six months. UPLIZNA is also approved for the treatment of Neuromyelitis Optica.
IgG4-Related Disease Emerging Drugs
- Obexelimab (XmAb5871) – Zenas BioPharma and Bristol Myers Squibb
Obexelimab is a bifunctional monoclonal antibody engineered to bind both CD19 and FcγRIIb – receptors broadly expressed across the B-cell lineage – to inhibit the activity of pathogenic cells implicated in multiple autoimmune diseases without depleting them entirely. This differentiated mechanism of action, paired with a self-administered subcutaneous injection regimen, positions obexelimab as a potentially widely applicable treatment across the autoimmune space.
Zenas BioPharma is currently conducting multiple Phase II and Phase III trials of obexelimab across several autoimmune indications, including IgG4-RD, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. In August 2023, The Lancet Rheumatology published findings from a Phase II study evaluating obexelimab in IgG4-RD patients. Based on encouraging results, a Phase III study is now ongoing to further investigate the efficacy and safety of subcutaneously administered obexelimab in this patient population.
Conclusion
The IgG4-Related Disease market insight reflects an evolving landscape where scientific understanding, clinical innovation, and regulatory progress are converging to transform patient outcomes. The landmark FDA approval of UPLIZNA marks a turning point – one that signals growing recognition of IgG4-RD as a condition deserving dedicated therapeutic solutions rather than repurposed agents. With a pipeline anchored by promising mechanisms such as B-cell inhibition and emerging biologics, and with epidemiological data confirming substantial and growing patient populations across the 7MM, the market is well-positioned for sustained expansion. Increasing physician awareness, improved diagnostic pathways, and ongoing investment in clinical research will remain the primary catalysts for market growth through 2034.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
